Jiangsu Yahong Meditech Co., Ltd. (688176.SS)

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of breast cancer; and AT-021 for the treatment of breast cancer and other solid tumors. The company also develops APL-1706 and APLD-2304 for non-muscle-invasive bladder cancer (NMIBC) diagnosis and surgery; APL-1202 for Untreated intermediate-risk NMIBC and neoadjuvant therapy before MIBC; and APL-2401 for urinary tumors. In addition, it develops APL-1202 for the treatment of free-living amoeba infection; APL-1401 for moderate to severe active ulcerative colitis; and APL-2301, an antibiotic for Acinetobacter baumannii infection. The company was incorporated in 2010 and is based in Shanghai, China.